Race Oncology (ASX:RAC) completed a drug discovery program targeting the Fat and Obesity associated (FTO) protein at Monash University's Fragment Platform, according to a Thursday filing with the Australian bourse.
The program used nuclear magnetic resonance screening to identify 39 chemical candidates that bind specifically to the FTO protein, the filing said.
The FTO protein is a key regulator in ribonucleic acid (RNA) epigenetics. Loss of control of RNA epigenetics is linked to several cancers and metabolic diseases.
The identification of the chemical candidates by Race Oncology provides a platform for developing new FTO-targeting drugs, the filing said.
Race Oncology plans to advance these candidates into a hit-to-lead medicinal chemistry program, though a final decision has not yet been made on progressing this expensive phase.
The company's shares rose almost 3% in recent Thursday trade.
Price (AUD): $1.40, Change: $+0.04, Percent Change: +2.94%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。